Figure 3. Epitope mappaing of the α5NC1-specific autoantibodies from the patient A5 using indirect (A) and inhibition (B) ELISA.
GP1 patient with classical anti-GBM disease is shown for comparison (A). In panel B, A5 patient serum was pre-incubated with various concentrations of the α1NC1 (δ), α5NC1 (●) EA-α5 (○), EB-α5 (▼) or the mixture of EA- and EB-α5 chimeras (●, dashed line). Binding to immobilized α5NC1 domain was measured using ELISA, and relative binding is calculated as a percentage of antibody binding to immobilized α5NC1 in the absence of NC1 monomers or chimeras in solution.
